Steroid 5-α reductase type 2 activity in biopsies from malignant and normal prostatic tissues

Bjelfman, 1997, Differential gene expression of steroid 5α-reductase 2 in core needle biopsies from malignant and benign prostatic tissue, J Clin Endocrinol Metab, 82, 2210 Titus, 2005, Steroid 5α-reductase isozymes I and II in recurrent prostate cancer, Clin Cancer Res, 11, 4365, 10.1158/1078-0432.CCR-04-0738 Thigpen, 1993, Characterization of Chinese hamster ovary cell lines expressing human steroid 5 α-reductase isozymes, J Biol Chem, 268, 17404, 10.1016/S0021-9258(19)85349-8 Imperato-McGinley, 1992, Prostate visualization studies in males homozygous and heterozygous for 5 alpha-reductase deficiency, J Clin Endocrinol Metabol, 75, 1022 Isaacs, 1983, Changes in the metabolism of dihydrotestosterone in the hyperplastic human prostate, J Clin Endocrinol Metab, 56, 139, 10.1210/jcem-56-1-139 Petrow, 1986, The dihydrotestosterone (DHT) hypothesis of prostate cancer and its therapeutic implications, Prostate, 9, 343, 10.1002/pros.2990090405 McNeal, 1988, Normal histology of the prostate, Am J Surg Pathol, 12, 619, 10.1097/00000478-198808000-00003 Söderström, 2001, Messenger ribonucleic acid levels of steroid 5α-reductase 2 in human prostate predict the enzyme activity, J Clin Endocrinol Metab, 86, 855 Thomas, 2005, Differential alterations in 5α-reductase type 1 and type 2 levels during development and progression of prostate cancer, Prostate, 63, 231, 10.1002/pros.20188 Ross, 1992, 5α-reductase activity and risk of prostate cancer among Japanese and US white and black males, Lancet, 339, 887, 10.1016/0140-6736(92)90927-U Fuganti, 2002, Twelve core prostate biopsy versus six systematic sextant biopsies, Braz J Urol, 28, 207 Furuta, 2001, Pharmacodynamic analysis of steroid 5α-reductase inhibitory actions of Z-350 in rat prostate, Eur J Pharmacol, 426, 105, 10.1016/S0014-2999(01)01208-0 Normington, 1992, Tissue distribution and kinetic characteristics of rat steroid 5α-reductase isozymes, J Biol Chem, 27, 19548, 10.1016/S0021-9258(18)41809-1 Pratis, 2000, Enzyme assay for 5α-reductase type 2 activity in the presence of 5α-reductase type 1 activity in rat testis, Steroid Biochem Mol Biol, 75, 75, 10.1016/S0960-0760(00)00139-4 Hirosumi, 1995, J. Steroid Biochem Mol Biol, 4, 357, 10.1016/0960-0760(94)00187-Q Lowry, 1951, Protein measurement with the Folin phenol reagent, J Biol Chem, 193, 265, 10.1016/S0021-9258(19)52451-6 Kellof, 2001, Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer, Urology, 57, 46, 10.1016/S0090-4295(00)00940-7 Bostwick, 1994, The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials, J Cell Biochem Suppl, 19, 283 Civantos, 1996, Histopathological effects of androgen deprivation in prostatic câncer, Semin Urol Oncol, 14, 22 Hellerstedt, 2002, The current state of hormonal therapy for prostate cancer, Cancer J Clin, 52, 154, 10.3322/canjclin.52.3.154 Nakamura, 2005, In situ androgen producing enzymes in human prostate cancer, Endocr-Relat Cancer, 12, 101, 10.1677/erc.1.00914 Andriole, 2004, Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (reduce) trial, J Urol, 172, 1314, 10.1097/01.ju.0000139320.78673.2a Torres, 2003, Development of a quantitative RT-PCR method to study 5 alpha-reductase mRNA isozymes in rat prostate in different androgen status, Prostate, 56, 74, 10.1002/pros.10221 Iehlé, 1999, Differences in steroid 5α-reductase iso-enzymes expression between normal and pathological human prostate tissue, J Steroid Biochem Mol Biol, 68, 189, 10.1016/S0960-0760(99)00030-8 Thompson, 2003, The influence of finasteride on the development of prostate cancer, N Engl J Med, 349, 215, 10.1056/NEJMoa030660 Andriole, 2004, Effect of the dual 5 alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer, J Urol, 172, 915, 10.1097/01.ju.0000136430.37245.b9 Presti, 1992, Multicenter, randomized, double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer, J Urol, 148, 1201, 10.1016/S0022-5347(17)36860-X Brufsky, 1997, Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate, Urology, 49, 913, 10.1016/S0090-4295(97)00091-5 Cote, 1998, The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels, Br J Cancer, 78, 413, 10.1038/bjc.1998.508 Shirakawa, 2004, Messenger RNA levels and enzyme activities of 5 α-reductase types 1 and 2 in human benign prostatic hyperplasia (BPH) tissue, Prostate, 58, 33, 10.1002/pros.10313